Cancer Network
Spotlight
CancerNetwork® Inaugural Face-OffContemporary Concepts in Hematologic OncologyReal-World Evidence in NSCLC Guides Clinical Decisions Register: ctDNA in Treatment Decisions and Response MonitoringTargeting NSCLC with Uncommon EGFR Mutations
Clinical
View MoreAcute Myeloid LeukemiaBrain CancerBreast CancerColorectal CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer
News
Clinical TopicsIntegrative CareGlobal BulletinAll NewsApproval Alert
Media
2 Minute DrillAround the PracticeBetween the LinesClinical ConsultExpert InterviewsFace OffMedical World NewsOncViewPodcastsReadout 360Year in Review
Conferences
Publications
All JournalsFor AuthorsTumor Board
CME/CE
Resources
Contemporary ConceptsInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
Subscribe
eNewsletterPrint Subscription

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2022 MJH Life Sciences and Cancer Network. All rights reserved.

Spotlight
  • CancerNetwork® Inaugural Face-Off
  • Contemporary Concepts in Hematologic Oncology
  • Real-World Evidence in NSCLC Guides Clinical Decisions
  • Register: ctDNA in Treatment Decisions and Response Monitoring
  • Targeting NSCLC with Uncommon EGFR Mutations
ClinicalSee All >
  • Acute Myeloid Leukemia
  • Brain Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancer
  • Gynecologic Cancer
  • Hematology
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Pediatric Cancers
  • Skin Cancer
  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.

Treatment Options for Early-Stage HER2-Positive Breast Cancer

Virginia Kaklamani, MD, DSc, provides a discussion on the frontline and maintenance therapies available for the management of early-stage HER2+ breast cancer.

EP. 1: Goals of Care for HER2+ Breast Cancer

February 1st 2022

Virginia Kaklamani, MD, DSc, provides an overview of the goals of care for HER2+ breast cancer.

EP. 2: HER2+ Breast Cancer: Frontline Treatment Options

February 1st 2022

A review of the currently available frontline treatment options for HER2+ breast cancer.

EP. 3: Clinical Trial Data in HER2+ Breast Cancer

February 8th 2022

Virginia Kaklamani, MD, DSc, provides an overview of the goals of care for HER2+ breast cancer.

EP. 4: HER2+ Breast Cancer and the Role of Maintenance Therapies

February 8th 2022

Dr. Virginia Kaklamani discusses the role of maintenance therapies for HER2+ breast cancer.

EP. 5: HER2+ Breast Cancer Clinical Pearls

February 15th 2022

Advice for community physicians treating HER2+ breast cancer.